New Immune-Targeting drug could boost stomach cancer treatment
Disease control
Not yet recruiting
This phase 3 trial tests whether adding the experimental drug ASP2138 to standard chemotherapy and immunotherapy (pembrolizumab) helps people with a specific type of advanced stomach or gastroesophageal junction cancer live longer without their disease worsening. The study enroll…
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC